Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Hisako Yoshida"'
Autor:
Kazuhiko Tsuruya, Hisako Yoshida
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-7 (2021)
Background In Japan, only less than 3% of patients undergoing maintenance dialysis select peritoneal dialysis (PD) as the mode of renal replacement therapy. Half of patients undergoing PD use a cycler for automated PD (APD). However, it remains uncle
Autor:
Toshiaki Nakano, Hokuto Arase, Hiroaki Tsujikawa, Takanari Kitazono, Shunsuke Yamada, Yasuhiro Kawai, Shoji Tsuneyoshi, Hisako Yoshida, Kazuhiko Tsuruya
Publikováno v:
Therapeutic Apheresis and Dialysis. 24:72-80
Preserving residual kidney function (RKF) is important in the management of patients on peritoneal dialysis. However, few studies have examined the association between serum albumin level and the risk of RKF loss. We prospectively recruited 104 patie
Autor:
Hisako Yoshida, Tohru Mizumasa, Toshiaki Nakano, Takanari Kitazono, Masatomo Taniguchi, Masahiro Eriguchi, Yusuke Kuroki, Kazuhiko Tsuruya, Kosuke Masutani
Publikováno v:
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 40(1)
Background:Deposition of advanced glycation end products (AGEs) is frequently found in the peritoneum of patients on peritoneal dialysis (PD). Angiogenesis is also observed in the peritoneum. However, the clinical significance of AGEs and angiogenesi
Autor:
Hiroaki Ooboshi, Hisako Yoshida, Kazuhiko Tsuruya, Narihito Tatsumoto, Shunsuke Yamada, Masanori Tokumoto, Takanari Kitazono
Publikováno v:
Therapeutic Apheresis and Dialysis. 21:71-78
As fibroblast growth factor 23 (FGF23) has been shown to induce cardiovascular disease directly in patients with chronic kidney disease, identification of factors and treatments that can modulate serum FGF23 (sFGF23) level is clinically important. Th
Autor:
Hiroaki Ooboshi, Kazuhiko Tsuruya, Hisako Yoshida, Shunsuke Yamada, Masanori Tokumoto, Takanari Kitazono, Kenji Ueki
Publikováno v:
Calcified Tissue International. 99:13-22
Myostatin is a member of the transforming growth factor-β family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia. It is up-regulated in the skeletal muscle of chronic kidney
Autor:
Hisako Yoshida, Kazuhiko Tsuruya
Background There is an increasing prevalence of dementia associated with population aging, and anti-dementia measures have now become of increasing importance in Japan. Chronic kidney disease (CKD) is a risk factor for cognitive impairment. Summary W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59bc7feb7c6626afc8f165af34d4eb1a
https://doi.org/10.1159/000485694
https://doi.org/10.1159/000485694
Autor:
Shunsuke Yamada, Hisako Yoshida, Akihiro Tsuchimoto, Masahiro Eriguchi, Kosuke Masutani, Kazuhiko Tsuruya, Takanari Kitazono, Kiichiro Fujisaki, Shigeru Tanaka, Kumiko Torisu
Publikováno v:
Renal Replacement Therapy, Vol 3, Iss 1, Pp 1-9 (2017)
Background How residual kidney function (RKF) functions in the prevention of anemia in peritoneal dialysis (PD) patients is unclear. In this study, we investigated the association between RKF and hemoglobin (Hb) level. Methods We performed a cross-se
Autor:
Yasuhiro Kawai, Takanari Kitazono, Hiroaki Tsujikawa, Hisako Yoshida, Shigeru Tanaka, Kazuhiko Tsuruya, Masatoshi Hara
Publikováno v:
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 39(2)
BackgroundResidual kidney function (RKF) is an important factor influencing both technique and patient survival in peritoneal dialysis (PD) patients. B-type natriuretic peptide (BNP) is considered a marker of cardio-renal syndrome. The relationship b
Autor:
Masanori Tokumoto, Takanari Kitazono, Shunsuke Yamada, Hisako Yoshida, Hiroaki Ooboshi, Kazuhiko Tsuruya
Publikováno v:
Nephrology. 20:639-645
Aim Sclerostin and dickkopf-1 (Dkk-1) are soluble inhibitors of Wnt-β-catenin signaling and are involved in decreased bone formation and bone volume in patients with various bone diseases. The clinical characteristics of sclerostin and Dkk-1 and the
Autor:
Makoto Hirakawa, Koji Mitsuiki, Hidetoshi Kanai, Masaharu Nagata, Kazuhiko Tsuruya, Yusuke Kuroki, Takashi Yoshiura, Hisako Yoshida, Takanari Kitazono, Tohru Mizumasa, Hideki Hirakata, Kei Hori
Publikováno v:
American Journal of Kidney Diseases. 65:312-321
Background Brain atrophy has been reported in patients with end-stage renal disease receiving hemodialysis, although its mechanism is unknown. However, little is known regarding brain atrophy in patients receiving peritoneal dialysis (PD). Therefore,